Novartis Ag

Connie Hong

Lu Huang

Tony Fleming

Aida Abujoub

John Blankenship

Brian Holmberg

Chonghui Zhang

Dexiu Bu

Brian Walter Granda

Haihui Lu

Dattananda Chelur

Jennifer Brogdon

Glenn Dranoff

Boris Engels

Carla Guimaraes

Regis Cebe

Barbara Brannetti

Xu Zhu

Michael R Greene

Amy Rayo

Andrew Marc Stein

Akash Sohoni

Attilio Bondanza

Olja Kodrasi

Elizabeth Dorothy Pratico

Hyungwook Lim

Serena De Vita

Anniesha Hack

Joni Waiee Lam

Sunyoung Jang

Andrew Price

Louise Treanor

The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.

Chimeric antigen receptors and uses thereof

The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

Binding molecules against BCMA and uses thereof

The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.

CD19 binding molecules and uses thereof

The present disclosure provides CD2 binding molecules that specifically bind to CD2, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD2 binding molecules, and pharmaceutical compositions comprising the CD2 binding molecules and the conjugates. The disclosure further provides methods of using the CD2 binding molecules to modulate CD2 signaling in order to treat a variety of immune (e.g., autoimmune), inflammatory and proliferative disorders. The disclosure yet further provides recombinant host cells engineered to express the CD2 binding molecules and methods of producing the CD2 binding molecules by culturing the host cells under conditions in which the CD2 binding molecules are expressed.

Variant CD58 domains and uses thereof

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

BCMA chimeric antigen receptors and uses thereof

Growing community of inventors

Somerville, MA, United States of America

Connie Hong